We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Niox Group Plc | LSE:NIOX | London | Ordinary Share | GB00BJVD3B28 | ORD 0.08P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.60 | 0.99% | 61.00 | 60.20 | 62.00 | 62.00 | 61.00 | 61.00 | 9,644 | 10:02:47 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 36.8M | 9.5M | 0.0224 | 27.23 | 256.17M |
Date | Subject | Author | Discuss |
---|---|---|---|
19/7/2023 09:41 | Every time there is a bit of profit taking it bounces right back up. Sure sign of strength. Dangerous trading this at the moment what with potential takeover not to mention looming dividend which will cover my flights to Aus and back! | earwacks | |
18/7/2023 17:16 | Finished at the days high hopefully a good sign | bc4 | |
18/7/2023 07:09 | Boom! Seems like we are breathing life into share price as well as folks lungs | edwardt | |
18/7/2023 07:02 | Would have liked some news on the home testing kit development. Not complaining. It comes when it comes. Just surprised. Will add significantly when it does to already fantastic increase to cash generation . Dont be too harsh on rampers. Remember this has still made a very small dent of about 5 percent of potential overall market! Also it sounds like the dividend is a permanent fixture whether at the same rate as the special Is maybe to be determined. If you bought in around 25p that’s a 10 percent divi. I averaged up all the way to 50p. Not sure I will top up from here. Just wait for an offer I hope. What a time to have 600 million tax offset! | earwacks | |
18/7/2023 06:10 | Looks a strong trading statement .... I particularly like the material upgrade bit! We indicated at the time of our AGM in May that adjusted EBITDA (1) would be significantly higher than management expectations at the start of the year. After two further full months of strong trading, particularly in the APAC region, management's expectations for the year end outturn have been subject to further material upgrade. | thedudie | |
13/7/2023 15:49 | Told you it was quality | edwardt | |
11/7/2023 15:53 | Mills is not on the board of Niox as he was with Bioquel. I think he has total confidence in Johnson. No idea how many companies would be interested in Niox but I but I don’t suppose AZN are the only ones. Mills was wrong about them not getting to 60p under their own steam. I am surprised that Paul Hill is kicking himself for not buying in. I bought some more in the small dip. They are still a great buy. Ok your not going to double your money now but still some big dividends or a buyout not to be sniffed at. Got to be minimum 70p now | earwacks | |
10/7/2023 08:15 | Looks like a bit of life in NIOX could be back on the move | bc4 | |
14/6/2023 19:20 | This is quality growth now so should compound over time irrespective of a bid. Happy to sit tight here. | edwardt | |
14/6/2023 14:50 | 98k sell this morning dented the share price a little . Then a 3,700,000 buy this afternoon steadied the ship. Great to get in a little top up below 60p. Effectively a 5% special dividend in September. Expecting £30 million cash pile by year end and thats without the home test launch. No indication yet on that. Mills says most of the money has been made on this now. That as maybe but still must be at least 20% upside without a bid. Dont think he expected this to get in the 60s without an offer on the table. This is and will be even more of a cash cow. Cant see how it wont get bought. Maybe waiting for confirmation on home test kit. | earwacks | |
08/6/2023 08:53 | Will Mills be encouraging a trade sale now the price has run up and less immediate upside left on the table? Home test kit will be important. | p1nkfish | |
07/6/2023 12:51 | It’s all worth a listen, but for those in a rush NIOX gets discussed around 17 minutes in. | badday | |
07/6/2023 07:54 | Very nice ... I didn't expect that quite so soon. Business is booming and throwing off cash. I think it will soon catch the eye of a trade buyer. | thedudie | |
07/6/2023 07:45 | Still before Home Test Kit too that can only add benefits. Lovely turn around. | p1nkfish | |
07/6/2023 06:53 | It tells you how much cash they are making | bc4 | |
07/6/2023 06:29 | Special divi, nice. | p1nkfish | |
06/6/2023 19:33 | Huge volume today changing hands at 62 8 which must be positive, wonder when we will get an rns... | allstar_07 | |
04/6/2023 07:24 | Plenty more to come I expect. 22 million cash after paying 1 million for disused business. Dividend to be announced, and launch of home test kit. On top of that would make a very attractive earnings enhancer to a large pharma. With the growth potential its still not really expensive for this sector | earwacks | |
30/5/2023 15:47 | Well after the tree shake it looks like we are back in the 60s nice rise today in a falling market, | bc4 | |
26/5/2023 13:25 | 30days iirc | allstar_07 | |
24/5/2023 16:54 | Think it has to stay at that share price for so many consecutive days. Probably a conspiracy not to let that happen :) | earwacks | |
24/5/2023 08:12 | Relentless rise. Buyout earlier than expected? | badday | |
23/5/2023 19:43 | From 4 years ago .... Oxford, UK - 19 December 2019: Circassia ...announces that it has granted nil-cost options ("Options") today over 4,322,767 ordinary shares in the Company ("Ordinary Shares") to Ian Johnson, who was appointed as Executive Chairman of the Company on 5 December 2019, under the 2019 Performance Share Plan. The Options have been granted at nil-cost and will vest on the third anniversary of the date of grant and are exercisable until the tenth anniversary of the date of grant. Vesting is subject to either the share price reaching 62.4p Nearly there I would say .... He will be happy if it passes this hurdle! | thedudie |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions